Drug Trial Radar · NCT07708714
Optimizing Hydroxyurea Therapy in Children With Sickle Cell Anemia In Malaria Endemic Areas: The NOHARM Maximum Tolerated Dose (MTD) Study
Last checked: Nov 20, 2026Latest source record: Jul 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
250
Planned (sponsor's estimate)
Start
May 13, 2026
Primary completion
Nov 30, 2030
Study completion Nov 30, 2032
Sponsor
- Lead sponsor
- Children's Hospital Medical Center, CincinnatiAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Makerere University; Indiana University; Indian Institute of Science; Mulago Hospital, Uganda
- First posted
- Jul 16, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 11 years, up to 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
NOHARM MTD is an extension of a previous study for children with Sickle Cell Anemia (SCA) who were enrolled in the NOHARM study. All children enrolled in NOHARM received hydroxyurea treatment at a fixed daily dose of 20 mg/kg/day. This dose was selected as a likely safe dose, but does not escalate hydroxyurea to maximum tolerated dose "MTD" as is commonly done in the US. Without this information, we cannot know whether hydroxyurea treatment at the MTD would be feasible (since it requires closer monitoring to avoid hematological toxicities), safe (since adverse events may be greater with MTD, risk of malaria may be altered by MTD, and risk of infections as a result of neutropenia could also be greater with MTD) or beneficial (MTD is associated with higher hemoglobin and fetal hemoglobin concentration).
Conditions
- Sickle Cell Disease
- Sickle Cell Anemia in Children
Interventions
hydroxycarbamideDrug
Hydroxyurea at optimized dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- Composite measure of organ damageTime frame: From enrollment, after 24 months and again after 48 months of study treatment.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Mulago Hospital Sickle Cell Clinic
Kampala, Uganda · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.